ShortageWatch RxUS drug shortage tracker, built on FDA data

← All shortages

Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection shortage

To Be Discontinued  1 presentations · 1 manufacturers · first FDA posting 2026-09-09 · last update 2026-09-09

Manufacturers: Merck Sharp & Dohme LLC

Stated reasons (per FDA): Not stated

📬 Get weekly shortage updates by email

Presentations

PresentationManufacturerStatusReasonNotes (FDA)Dates
RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)Merck Sharp & Dohme LLCTo Be Discontinued
 —To be discontinued on or near late September 2026.Posted 09/09/2026
Updated 09/09/2026
Discontinued 09/09/2026

Source: FDA Drug Shortages Database · raw openFDA records

Get the weekly shortage roundup: a free email of FDA shortage changes (open form)